诚信认证：
工商注册信息已核实！
Osilodrostat (LCI699)，928134-65-0，10mM in DMSO
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 总代理 | 中国 | 现货 |
性能特点
InformationOsilodrostat (LCI699) LCI699(Osilodrostat) is a potent inhibitor of 11β-hydroxylase (
| 货号 | 规格 | CAS号 | 价格 | 操作 |
|---|---|---|---|---|
| O426958-1ml | 1ml | 928134-65-0 | ￥720.90 | 询底价 |
中文名：Osilodrostat (LCI699)
英文名：Osilodrostat (LCI699)
英文别名：osilodrostat|LCI699|928134-65-0|(+)-Osilodrostat|Isturisa|LCI-699|LCI699-NX|LCI-699-NX|Osilodrostat free base|LCI 699|5YL4IQ1078|(R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile|UNII-5YL4IQ1078|CHEMBL3099695|4-[(5R)-6,7-dihydro-5H-p
纯度：10mM in DMSO
货号：O426958
Cas号：928134-65-0
存储温度：-80℃储存
产品介绍：
Information
Osilodrostat (LCI699) LCI699(Osilodrostat) is a potent inhibitor of 11β-hydroxylase (CYP11B) , an enzyme catalyzing the final step of cortisol synthesis.
Targets
11β-hydroxylase 2.5 nM
In vitro
LCI699 also inhibits aldosterone synthase (CYP11B2) other than CYP11B1.
In vivo
LCI699 is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyzes the final step of cortisol synthesis, and has a half-life of ∼4 hours. It decreases blood pressure (BP) in patients with essential hypertension and primary aldosteronism. Treatment with LCI699 is well tolerated, it is demonstrated efficacy with a satisfactory safety and tolerability profile in the proof-of-concept study in Cushing\'s disease. The administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.
查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/O426958.html
Osilodrostat (LCI699)，928134-65-0，10mM in DMSO信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Osilodrostat (LCI699)，928134-65-0，10mM in DMSO报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途
